Back to search
FDAFDA · Food and drugs·Recall number D-0959-2017

EliquisTablets 5mg, 60 count bottle, Rx Only, Marketed by: Bristol-Meyers Squibb Company Princeton, NJ 08543 USA and Pfizer Inc. New York, NY 10017 USA, NDC 0003-0894-21

Published July 19, 2017 · Recall initiated: June 5, 2017

Summary

FDA records drug Class I recall D-0959-2017, published July 19, 2017 and initiated June 5, 2017. Recalling firm: Bristol-myers Squibb Company; Status: Terminated; Reported quantity: 48,180 bottles; Lot: Lot: HN0063, EXP. 09/2019. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Label Mix-up: One bottle of Eliquis 5 mg tablet was found to contain lower-strength Eliquis 2.5 mg tablets only instead of the labeled 5 mg tablets.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Bristol-myers Squibb Company
Distributor
Nationwide in the US
Lot
Lot: HN0063, EXP. 09/2019
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was EliquisTablets 5mg, 60 count bottle, Rx Only, Marketed by: Bristol-Meyers Squibb Company Princeton, NJ 08543 USA and Pfizer Inc. New York, NY 10017 USA, NDC 0003-0894-21 recalled?

Yes. FDA published recall D-0959-2017 on July 19, 2017. Reported hazard: Labeling: Label Mix-up: One bottle of Eliquis 5 mg tablet was found to contain lower-strength Eliquis 2.5 mg tablets only instead of the labeled 5 mg tablets.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail